A fatal case of amniotic fluid embolism syndrome in a 41-year-old woman during emergency caesarean section is reported. Review of the literature reveals that classical risk factors may be absent, diagnosis may be difficult, and that acute right heart failure may be less important than global myocardial dysfunction. In view of these features and the high mortality, management guidelines for amniotic fluid embolism syndrome are presented. A high index of suspicion for this condition is required and early management should be supported by close haemodynamic monitoring.
CASE PRESENTATION
A 55 kg, 41-year-old woman (gravida 2, para 1) with the complications of grade IV placenta praevia, gestational diabetes mellitus, polyhydramnios and iron deficiency anaemia, was admitted at 33 weeks gestation for rest and observation. Amniocentesis at 16/40 had revealed a normal male 46XY karyotype. During admission her urinalysis and blood pressure (120/80 mmHg) were normal. Her coagulation profile, serum urea and electrolytes, liver function tests, and blood film were normal. Her haemoglobin was 12.8 g/dl, and platelet count was 251 x 10 9 /1. Thirteen days following admission it was decided that a caesarean section should be performed because of concerns regarding feto-placental reserve, based on diminished foetal movements and a reduction in fetal heart rate variability, over the previous three days. Caesarean section was performed under general anaesthesia with the delivery of a healthy 3350g male infant. Ten units of intravenous syntocinon were given upon delivery.
Immediately following delivery of the placenta there was a precipitous fall in end-tidal CO 2 from 32 to 20 mmHg, together with no recordable blood pressure, and sinus tachycardia of 120/min. Auscultation of her chest revealed bilateral air entry and no bronchospasm. She had received 1.0 litre of crystalloid intravenously at this stage and total blood loss was estimated at 600 ml.
Resuscitation included ventilation with 100070 oxygen, infusion of 1.5 litres of colloid and an additional 1.0 litre of crystalloid over 30 minutes, by which time her systolic blood pressure had risen to 80 mmHg. No further blood loss was evident. A syntocinon infusion was commenced and on completion of surgery she was transferred to the Intensive Care Unit (ICU).
On arrival in lCU, having received an infused volume of 3.5 litres, her blood pressure was 100 mmHg systolic and she remained tachycardic (l20/min), hypoxic (pulse oximetry 90%) and severely acidotic (pH = 6.99). Auscultation of the chest revealed basal crepitations. The uterine fundus was just below the umbilicus and despite continuing slow loss per vaginam and some oozing from the wound, the total observed blood loss was less than 1000 ml. Her admission APACHE 11 score was 25.
Initial investigations revealed a microangiopathic haemolytic anaemia with a haemoglobin (Hb) level of 6.2 g/dl, thrombocytopaenia (73x10 9 /1) and coagulation studies consistent with a severe disseminated intravascular coagulopathy (Table 1) . Her liver function tests revealed mild hyperbilirubinaemia and elevation of AST.
Over the next 30 minutes, two litres of colloid were required to maintain her systolic blood pressure at 100 mmHg. A central venous catheter (CVC) was inserted and her central venous pressure (CVP) was found to be only 1 mmHg. Transfusion with six units of packed red cells, five units of fresh frozen plasma and five units of platelets was commenced.
Four hours postoperatively, and after a total transfused volume of 6.5 litres, a pulmonary artery (PA) catheter was inserted and the haemodynamic picture obtained suggested persistent hypovolaemia ( Table 2 , 4 hours). No air bubbles were aspirated from the CVC or the PA catheter. Transfusion was continued, an adrenaline infusion commenced, and intravenous calcium given. Cl = cardiac index (l/min/m'), SVI = stroke volume index (ml/beat/m') (a) = cumulative infused volume, (b) = I'g/min At the sixth postoperative hour laboratory investigations showed some improvement in her anaemia, coagulopathy, and acidosis (Table 1, 6 hours), but persistent hypotension and oliguria. At nine hours, and after 11 litres of intravenous fluids, her blood pressure remained low. Her haemodynamic profile (Table 2, 9 hours) revealed an elevated CVP and PA wedge pressure and myocardial dysfunction (low cardiac and stroke volume indices). Echocardiography, unfortunately, was not available. The adrenaline infusion was increased and broad spectrum antiobiotics were given prophylactically.
Over the next two days her coagulopathy and acidosis resolved, her myocardial function improved and her inotrope requirements diminished. However, 14 Post mortem examination revealed evidence of diffuse alveolar damage, disseminated intravascular coagulation, and foci of foetal squames in the pulmonary vessels. Although supportive, these findings were insufficient to confirm a pathological diagnosis of amniotic fluid embolism syndrome. There was no evidence of pulmonary thromboembolism, and examination of the myocardium was unremarkable. There was no occult site of blood loss or evidence of a septic focus and the adrenal glands were normal.
DISCUSSION
This case of probable amniotic fluid embolism syndrome was characterized by sudden onset of hypotension (out of proportion to the blood loss), hypocapnoea, and disseminated intravascular coagulation. In spite of massive volume replacement, hypotension persisted and severe myocardial impairment was evident on haemodynamic studies. While hypovolaemia requiring massive transfusion was present in this case, the rapid onset of her coagulopathy and hypotension, in excess of the observed blood loss suggested an alternative diagnosis. Some features suggested the possibility of either air-or thrombo-embolism or even an acute cardiomyopathy, but most of the findings suggested amniotic fluid embolism syndrome.
Clinical Features and Risk Factors
The incidence of amniotic fluid embolism syndrome has been reported between 1:8000' and 1:80000 2 live births. Mortality may be as high as 860/0 3 with up to 500/0 in the first hour 4 . In Australia, from 1970-1990, amniotic fluid embolism contributed to 7.50/0 of direct maternal mortality. This accounted for 34 out of 427 direct maternal deaths and 0.67 deaths per 100,000 pregnancies 5 • The classical description is sudden onset of dyspnoea, cyanosis and hypotension out of proportion to the blood loss, followed quickly by cardiorespiratory arresC. Up to 200/0 of patients will have seizures 6 and up to 400/0 will have a consumptive coagulopathy3,6 with bleeding per vaginam, and from incisions and intravenous 'catheter sites. If the initial phase is survived, a non-cardiogenic pulmonary oedema will follow in up to 700/0 of patients 6 • Acute renal failure secondary to prolonged hypotension may also occur 7 • This syndrome has been traditionally associated with older, multiparous mothers with large babies, following a vigorous labour using oxytocics. Despite the presence of a number of classical risk factors in the case presented, Morgan 3 reviewed predisposing factors in 272 cases and found no significant association with tumultuous labour, the use of uterine stimulants or size of the newborn.
Of the 34 fatal cases reported in Australia from 1970-1990 5 ,8-1\ most (760/0) were multiparous but the maternal age range was wide (20-44 years) and oxytocics were used to augment labour in only 12 (350/0). Six cases (140/0) occurred with caesarean section, 16 (440/0) occurred during labour, and 9 (260/0) occurred during, or soon after, vaginal delivery. Of the remaining cases, two occurred at 48 hours beyond delivery and one occurred befor labour began. Convulsions were reported in 4 (11 0/0) cases and coagulopathy in 12 (350/0). Amniotic fluid embolism has also been reported to occur following therapeutic abortion at 14 weeks gestation'4 and following closed abdominal trauma's. In summary, the presentation of amniotic fluid embolism syndrome can be quite variable and risk factors may be absent. Since the description of amniotic fluid embolism syndrome in 1941 by Steiner and Lushbaugh' there have been many animal experiments involving the intravenous injection of amniotic fluid and meconium. They demonstrated that injection of human amniotic fluid and meconium into rabbits and dogs led to death in most cases.
Earlier authors assumed that the pathophysiology was primarily severe pulmonary hypertension secondary to occlusion or spasm of the pulmonary vessels resulting in acute right heart failure. This was based on the findings of significantly raised pulmonary vascular resistance, central venous pressure and pulmonary artery pressures in animals injected with amniotic fluid and meconium'6,17.
However, most animal studies are inconsistent and difficult to interpret because of the following problems: use of human or heterologous amniotic fluid; use of non-physiological volumes of fluid; use of nonpregnant models; and quite variable haemodynamic responses.
There are several animal studies involving injection of fresh autologous amniotic fluid into pregnant animals,s-20, which have demonstrated no significant changes in cardiac or respiratory function. Hankins et al 20 , recently showed a marked pressor response in both pulmonary and systemic circulation following fresh autologous amniotic fluid injection (2.5 mllkg) in pregnant goats. This response was greater with injection of amniotic fluid containing meconium, which, in addition, caused transient left ventricular dysfunction. Injection of cell-free placental extracts into pregnant rabbits also results in rapid death's.
Although amniotic and/or fetal matter in the maternal circulation is a sine qua non for amniotic fluid embolism syndrome it is not a pathognomonic finding. The presence of fetal matter in the pulmonary vasculature of peripartum women who are asymtomatic 2l is evidence that the entry of amniotic fluid into the maternal circulation does not necessarily lead to clinical amniotic fluid embolism. In the light of this, we should therefore distinguish between subclinical amniotic fluid emboli and a clinical amniotic fluid embolism syndrome-as in the case of air or fat embolism syndromes.
The primary causative agent(s) are unknown but could possibly be: 1. amniotic fluid; 2. placental tissue; 3. meconium; and/or 4. an excessive maternal reaction to any of the above.
In order for amniotic fluid to enter the maternal circulation there must be: 1. rupture of membranes, and 2. rupture of uterine veins. The possible sites of entry into the maternal circulation are tears in the lower uterus and endocervix and the uterine veins at the site of placental separation22.
Haemodynamic changes
Clark 6 has put forward a biphasic model of the haemodynamic changes in amniotic fluid embolism syndrome that refutes the previous theories of pure mechanical obstruction of the pulmomary vasculature. He proposed that there is initial pulmonary vasoconstriction in response to amniotic fluid, giving rise to transient pulmonary hypertension and profound hypoxia.
This proposed phase is brief, and with delay in insertion of a pulmonary artery catheter, accounts for the absence of supporting haemodynamic data from humans. The aetiology of the raised pulmonary vascular resistance is unclear. It has been postulated to be due to mechanical obstruction of the pulmonary artery, or pulmonary vasospasm secondary to fetal antigen, or production of vasoactive substances such as leukotrienes 23 • Hankins et apo demonstrated simultaneous rises in both pulmonary and systemic vascular resistance in response to injection of amniotic fluid into pregnant goats, which would be more consistent with vasoconstriction and not obstruction. This initial phase and its resulting hypoxia is likely to be the cause of the high early mortality.
The second haemodynamic phase proposed by Clark describes the onset of left ventricular dysfunction and secondary pulmonary hypertension. A number of recent reports of this syndrome have shown evidence of left ventricular dysfunction without right ventricular failure or severe pulmonary hypertension 20 . 23
• 24
• Girard et aP' reported a patient with amniotic fluid embolism syndrome and temporary left ventricular failure including echocardiographic features of a cardiomyopathy. In this patient myocardial biopsy and viral cultures were normal, as was a follow-up echocardiograph ten days later.
Thus the second phase is one of left ventricular or global myocardial dysfunction as appears in the case presented. The aetiology of this myocardial dysfunction is unknown. Clark et al' hypothesize that it may be secondary to the initial period of hypoxia, or depression of the myocardium by amniotic fluid co mponent(s). Depression of myocardial contractility by amniotic fluid has been demonstrated 25 and would support a direct myocyte depressant effect. It could also be due to circulating endogenous myocardial depressant factors, as seen in sepsis26. Another possible mechanism is a reduction in left ventricular compliance due to left shift of the interventricular septum following (phase one) right ventricular failure and dilatation.
Prior to the recognition of myocardial dysfunction as a significant feature of amniotic fluid embolism syndrome, pulmonary oedema was thought to have been due to an alveolar-capillary leakage secondary to acute microvascular emboli or fluid overload during resuscitation 3 • While acute pulmonary hypertension and left ventricular failure can produce hydrostatic pulmonary oedema, vasoactive inflammatory mediators can produce a pulmonary capillary leak, and all of these factors may be involved in the respiratory dysfunction seen in this syndrome.
There is a recent case report27 of the apparent successful use of cardiopulmonary bypass and pulmonary thromboembolectomy in the management of presumed amniotic fluid embolism, with the features of post partum shock, hypoxaemia and coagulopathy. However, pulmonary thromboembolism is not a feature in other case reports that include haemodynamic data or post mortem findings.
Coagulopathy
In Morgan's review 3 , 370/0 of patients were reported to have had a coagulopathy, and the incidence of lifethreatening disseminated intravascular coagulation is approximately 10%2.
In vitro studies have found that amniotic fluid can shorten whole blood clotting time, produce a thromboplastin effect, induce platelet aggregation, release Factor Ill, activate the complement cascade, and activate Factor X 28 . 29 . Trophoblastic tissue is also known to have strong thromboplastin effects and entry of trophoblastic tissue into the maternal circulation may also account for the consumptive coagulopathy observed 6 . Lockwood et apo have recently postulated that there is sufficient procoagulant in amniotic fluid to account for the coagulopathies seen, although this has previously been disputed 3 \ Coagulation studies will often reveal (as in the case described) prolonged prothrombin and activated partial thromboplastin times, thrombocytopaenia, decreased fibrinogen, and raised fibrin degradation products.
Diagnosis
With the current absence of reliable and specific diagnostic tools, the diagnosis is primarily clinical and one of exclusion. Diagnosis is made difficult by the variable presentation.
The differential diagnosis includes: haemorrhagic shock, placental abruption, pulmonary thrombo-embolism, anaphylaxis, air embolism, acute myocardial infarction, aspiration pneumonitis, sepsis syndrome and cardiomyopathies; and if seizures are a feature, eclampsia or toxicity from local anasthetic agents.
In the past the finding of fetal matter, particularly squamous cells, in the maternal pulmonary circulation has been considered diagnostic. However, there are reports of squamous cells and fetal matter being found in the pulmonary arteries of pregnant women who do not have amniotic fluid embolism syndrome-having pulmonary artery catheterization for other reasons l2 . It has even been suggested that any method of collecting central venous blood, or indeed venepuncture, will introduce squamous cells into the maternal circulation 12. Masson 22 contends that pulmonary capillary blood from a wedged pulmonary artery catheter sample diminishes the chance of contamination, and that the finding of large numbers of squames, especially when accompanied by mucin and hair or coated with neutrophils, is strongly suggestive of this syndrome. Diagnosis at post mortem is supported, but not conclusive, with the finding of fetal material in the maternal pulmonary circulation.
Recently, it has been shown that four patients with this syndrome had raised levels of sialyl Tn antigen in their serum, detected by assay with a monoclonal antibody TKH-211. This demonstrates that release of meconium or amniotic fluid derived mucin into the maternal circulation has occurred, and is proposed by Kobayashi et aI, as a "simple non-invasive sensitive method for amniotic fluid embolism". Kanayama et al l4 also demonstrated in four subjects that the presence of zinc coproporphyrinl4-as another indicator of meconium in the maternal plasma-may also be a sensitive test.
Further work is required to confirm the predictive power of these tests, prior to their widespread application. Diagnostic laboratory tests may be of some confirmatory value but currently are of limited value in the early management of amniotic fluid embolism syndrome, where the diagnosis must be made on primarily clinical grounds.
Management
Amniotic fluid embolism syndrome should be suspected in the differential diagnosis of any lifethreatening peri-partum disorder. Treatment is primarily symptomatic and aimed at the common goals of restoration of oxygenation, blood volume, cardiac output and correction of coagulopathies. Delivery should be expedited as soon as possible and the patient transferred to an appropriate intensive care ward following delivery and initial stabilization. Due to the high risk of respiratory failure, the patient should be intubated and ventilated initially with 100070 oxygen. Care must be taken to prevent traumatic haemorrhage during intubation and insertion of intravascular catheters.
Urinary catheterization is essential and invasive haemodynamic monitoring is beneficial. In a series of five patients with 100% survival, therapy was guided by intra-arterial and pulmonary artery catheterization ls .
Blood volume deficit and significant coagulopathies should be corrected as required with intravenous fluids and blood products. It has been suggested that lowdose heparin be commenced once bleeding is under control 29 • However, there is no further evidence in the literature to support this.
If hypotension persists, inotropic therapy to correct myocardial dysfunction and peripheral vascular failure will be necessary.
CONCLUSION
Amniotic fluid embolism syndrome is a lifethreatening but potentially reversible condition, and is a significant cause of maternal mortality. Classical risk factors may be absent and presentation is quite varied.
The pathophysiology remains poorly understood. The role of amniotic fluid is controversial. The syndrome may be due to any number of amniotic fluid components released into the circulation or an abnormal response by the patient. Recent reports suggest that acute right heart failure is less important than global myocardial dysfunction.
The diagnosis of this condition is a clinical one. A high index of suspicion is required and correct management of these patients in the first few hours is imperative, including accurate haemodynamic monitoring. The need for rapid diagnosis and treatment supports the establishment of fully equipped Intensive Care Units at major obstetric hospitals.
